Takeaways The Teva Canada–Samsung Bioepis deal makes Opuviz (aflibercept biosimilar to Eylea) a commercially available, lower‑cost alternative in Canada’s wet AMD, DME, and retinal vein occlusio...
Takeaways Sobi’s Empaveli is now positioned to move from import‑only, limited‑access status into publicly funded, pan‑Canadian treatment for C3 glomerulopathy and primary IC‑MPGN, one ...
Takeaways Ebglyss is now positioned to move from province‑specific coverage into broad, pan-Canadian reimbursement, which should materially expand Lilly’s eczema market and patient access. ...
Takeaways: Lilly now offers Canadian pediatric endocrinologists a once‑weekly injectable that addresses both glycemic control and weight – two core drivers of aggressiv...
Takeaways: The program integrates virtual veterinary support into routine store visits, enabling faster care, expert guidance, and greater customer confidence. For Vetster, the expansion into 14...
Takeaways: Quebec’s listing of PrOKEDI on the RAMQ formulary is a key commercial milestone for Bausch Health, turning a specialized, once‑monthly long‑acting risperidone into a publicl...
Takeaways: Cipher’s pCPA LOI for Epuris is a market inflection point that should expand revenue and prescription volume by shifting isotretinoin from patchy, private-pay cove...
Takeaways: The Canadian approval of Besremi gives PharmaEssentia a new, targeted therapy in the chronic myeloproliferative neoplasm space, expanding its hematology/oncology footprint beyond Taiw...
Takeaways: This approval expands Padcev from later-line urothelial cancer into earlier-stage muscle-invasive bladder cancer, which should broaden Pfizer’s addressable market in Canada and streng...
Shots: Takeaways: Sevmia’s approval makes Apotex the first Canadian generic challenger in Wegovy, which should increase price competition, widen access to semaglutide for ch...